ZNTL — Zentalis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Zentalis Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Zentalis Pharmaceuticals Q2 EPS USD -1.85
Zentalis Pharmaceuticals Inc expected to post a loss of $1.04 a share - Earnings Preview
Brief: Zentalis Pharmaceuticals Appoints Kimberly Freeman As Chief Strategy Officer
Brief: Zentalis Pharmaceuticals On June 15 Entered Agreed to Terminate Its Collaboration With Zentera Therapeutics
Brief: Zentalis Pharmaceuticals Announces Pricing Of Underwritten Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Cenovus Energy, Compass Pathways,
U.S. STOCKS ON THE MOVE-NovoCure, Intuit, Splash Beverage
U.S. STOCKS ON THE MOVE-TScan Therapeutics, Palantir, Coinbase Global
Zentalis up on dose selection study data for ovarian cancer therapy
Brief: Zentalis Says Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy
Live Markets: Digimarc among top 'squeeze' targets -S3 Partners
Brief: Zentalis Pharmaceuticals Q1 EPS USD -1.07
Brief: Zentalis Pharmaceuticals Reports Q1 2023 Financial Results And Operational Updates
Zentalis Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Zentalis Pharmaceuticals Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting
Brief: Zentalis Pharmaceuticals Inc - Has Operating Accounts With Svb With Minimal Cash Balance Versus Co's Total Cash & Cash Equivalents As Of Dec 31, 2022
Brief: Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results And Operational Updates